Recently, for the first time, a CRISPR/Cas9 short deletion system interrupts the BCR/ABL1 oncogene in primary leukemic stem cells Sca1+ from a CML mouse model and CD34+ from human CML patients. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.